AEON Biopharma names former FDA neuroscience leader Paul Lee acting chief regulatory officer
AEON•Paul Lee named acting chief regulatory officer
AEON Biopharma named Paul Lee as acting chief regulatory officer through Clintrex Research.
Lee previously served at the FDA as deputy director of the Office of Neuroscience. He also led the FDA’s Division of Neurology 2.
The role includes leading regulatory strategy for ABP-450, a biosimilar to BOTOX for therapeutic use.
